Nicotinamide, a vitamin B3 derivative, has been investigated for its potential to prevent skin cancer , though large-scale evidence remains scarce. To clarify its clinical efficacy, a study examined nicotinamide supplementation for skin cancer prevention in the general population and solid organ transplant recipients, including 33,822 participants. The study found that oral nicotinamide 500 mg twice daily was associated with a 14% overall reduction in skin cancer risk. When started after a first skin cancer diagnosis, the risk reduction increased to 54%, though the benefit declined with subsequent cancers.
The greatest reduction was observed for cutaneous squamous cell carcinoma (cSCC), followed by basal cell carcinoma. Among solid organ transplant recipients, no significant overall benefit was seen, but early nicotinamide use was linked to a lower incidence of cSCC. These findings…
